Pharmaceuticals, Biotechnology and Life Sciences
Entrome SA, a clinical-stage biopharmaceutical company will work with Memorial Sloan Kettering Cancer Center (MSK) in New York City to evaluate the potential of gut microbiome-derived antigens for development as cancer immunotherapies.
Arix Bioscience said Wednesday that its portfolio company Artios Pharma Ltd, has entered in-licensing agreement of a small-molecule ATR inhibitor programme from The University of Texas MD Anderson Cancer Center and ShangPharma.
Sandoz Tuesday said it got approval from US Food and Drug Administration for its biosimilar Ziextenzo, which is in particularly significant since Sandoz short-acting filgrastim Zarxio is the first biosimilar to surpass its reference biologic in US market share.
4D pharma Wednesday said that its clinical study with Merck to test MRx0518 combined with Keytruda further support its continued investment into our oncology franchise.
Biogen and Alkermes got approval from USFDA for Vumertiy, a novel oral fumarate with a distinct chemical structure, for the treatment of relapsing forms of multiple sclerosis (MS), to include clinically isolated syndrome, relapsing-remitting disease and active secondary progressive disease.
Amgen said in a press release Tuesday it’s total revenues decreased 3% to $5.7 billion compared with the same period last year, reflecting the impact of biosimilar and generic competition against key products.
Q-linea AB has received the official response including a number of clarifications and very positive feedback from the US Food and Drug Administration, FDA, regarding the company’s planned pivotal clinical trial with ASTar in the United States.
Ubiquigent and LEO Pharma A/S have entered into an option agreement granting LEO Pharma access to two novel compounds, which comes after an earlier agreement between the parties entered into as part of LEO Pharma Open Innovation, without disclosing financial terms.
There are many health and safety concerns surrounding seniors living alone. According to the Administration on Aging, approximately 20 percent of men and 36 percent of women over the age of 65 currently live alone, and accidents and close calls are among their biggest risks.
European Commission has approved a third indication for Dupixent® (dupilumab) for the treatment of chronic rhinosinusitis with nasal polyposis (CRSwNP). Dupixent is indicated as an add-on therapy with intranasal corticosteroids for the treatment of adults with severe CRSwNP for whom therapy with systemic corticosteroids and/or surgery do not provide adequate disease control. It is also approved for moderate-to-severe atopic dermatitis and severe asthma.